Cost Comparison of Intravitreal Aflibercept With Bevacizumab and Ranibizumab for the Treatment of Wet Age-Related Macular Degeneration

Shaikh, Adeel H.; Toussaint, Brian; Miller, Daniel M.; Petersen, Michael R.; Foster, Robert E.; Riemann, Christopher D.; Hutchins, Robert K.; Sisk, Robert A.

doi:10.3928/23258160-20150101-10

Cited by 15 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cost-effectiveness is an issue that is of concern. The cost of these anti-VEGF therapeutics varies, limiting their use [ 25 ]. Ziv-aflibercept is a recombinant fusion protein that is reported to improve visual acuity in patients with neovascular AMD and to be a cheaper alternative to the same molecule aflibercept [ 26 , 27 ].…”

Section: Resultsmentioning

confidence: 99%

Retinal and choroidal angiogenesis: a review of new targets

et al. 2017

View full text Add to dashboard Cite

Retinal and choroidal neovascularization are a major cause of significant visual impairment, worldwide. Understanding the various factors involved in the accompanying physiopathology is vital for development of novel treatments, and most important, for preserving patient vision. The intraocular use of anti-vascular endothelial growth factor therapeutics has improved management of the retinal and choroidal neovascularization but some patients do not respond, suggesting other vascular mediators may also contribute to ocular angiogenesis. Several recent studies examined possible new targets for future anti-angiogenic therapies. Potential targets of retinal and choroidal neovascularization therapy include members of the platelet-derived growth factor family, vascular endothelial growth factor sub-family, epidermal growth factor family, fibroblast growth factor family, transforming growth factor-β superfamily (TGF-β1, activins, follistatin and bone morphogenetic proteins), angiopoietin-like family, galectins family, integrin superfamily, as well as pigment epithelium derived factor, hepatocyte growth factor, angiopoietins, endothelins, hypoxia-inducible factors, insulin-like growth factors, cytokines, matrix metalloproteinases and their inhibitors and glycosylation proteins. This review highlights current antiangiogenic therapies under development, and discusses future retinal and choroidal pro- and anti-angiogenic targets as wells as the importance of developing of new drugs.Electronic supplementary materialThe online version of this article (doi:10.1186/s40942-017-0084-9) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Retinal and choroidal angiogenesis: a review of new targets

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Several cost-effective analyses studies compared the less frequent injections of aflibercept with ranibizumab and bevacizumab. 154 – 156 All studies agreed that irrespective of the treatment protocol used, bevacizumab is cost-efficient in a comparison with aflibercept, which in turn is more cost-efficient than ranibizumab. 154 – 156 …”

Section: Treatment Of Wet Amdmentioning

confidence: 99%

Recent developments in age-related macular degeneration: a review

Al-Zamil¹,

Yassin²

2017

CIA

335

251

View full text Add to dashboard Cite

Background: Visual impairment in elderly people is a considerable health problem that significantly affects quality of life of millions worldwide. The magnitude of this issue is becoming more evident with an aging population and an increasing number of older individuals. Objective: The objective of this article was to review the clinical and pathological aspects of age-related macular degeneration (AMD), diagnostic tools, and therapeutic modalities presently available or underway for both atrophic and wet forms of the disease. Methods: An online review of the PubMed database was performed, searching for the key words. The search was limited to articles published since 1980 to date. Results: Several risk factors have been linked to AMD, such as age (.60 years), lifestyle (smoking and diet), and family history. Although the pathogenesis of AMD remains unclear, genetic factors have been implicated in the condition. Treatment for atrophic AMD is mainly close observation, coupled with nutritional supplements such as zinc and antioxidants, whereas treatment of wet AMD is based on targeting choroidal neovascular membranes. Conclusion: Identification of modifiable risk factors would improve the possibilities of preventing the progression of AMD. The role of anti-vascular endothelial growth factor (anti-VEGF) agents has transformed the therapeutic approach of the potentially blinding disease "wet AMD" into a more favorable outcome.

show abstract

“…Age-related macular degeneration (AMD) is one of the most common causes of severe visual loss in middle- and old-aged populations, and often leads to severe impairments in daily life 1,2 . Currently, the first-line treatment for neovascular AMD (nAMD) is intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs, including bevacizumab, ranibizumab, and aflibercept 3–5 .…”

Section: Introductionmentioning

confidence: 99%

Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study

Lai

Hsieh

Yang

et al. 2019

Sci Rep

View full text Add to dashboard Cite

This study evaluated the characteristic changes in optical coherence tomography (OCT) biomarkers in neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor drugs and their relationship with visual outcomes at 1-year follow-up in a real-world setting. We retrospectively reviewed the medical records of 126 eyes with nAMD treated with either intravitreal ranibizumab or aflibercept, including ophthalmologic examinations and spectral-domain OCT at baseline and months 3, 6, and 12 after first injection. Treatment response of intraretinal cysts (IRCs), subretinal fluid (SRF), and pigment epithelial detachment (PED), and the correlation between best-corrected visual acuity (BCVA) changes and these OCT biomarkers were analyzed. After an average of 5.1 ± 1.5 injections, 33.3% of eyes with PED showed resolution at month 12, a significantly lower proportion than for IRCs (53.8%) or SRF (51.6%). BCVA improvement at 1 year was negatively associated with PED at baseline and with IRCs or PED at month 12. Persistence of IRCs at month 12 was associated with degeneration morphology of IRCs at baseline and non-resolved cysts at month 3 after loading. In conclusions, IRCs and PED are associated with poor visual improvement in nAMD in a real-world setting. Both IRCs and SRF responded better than PED to anti-VEGF therapy.

show abstract

Cost Comparison of Intravitreal Aflibercept With Bevacizumab and Ranibizumab for the Treatment of Wet Age-Related Macular Degeneration

Abstract: Aflibercept may allow a modest extension of the treatment interval, but cost makes IVA an expensive alternative without a visual benefit compared with IVB in patients with active wet AMD.

Cited by 15 publications

References 11 publications

Retinal and choroidal angiogenesis: a review of new targets

Retinal and choroidal angiogenesis: a review of new targets

Recent developments in age-related macular degeneration: a review

Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study

Contact Info

Product

Resources

About